Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Athersys to Present at 17th Annual BIO CEO & Investor Conference

ATHXQ

CLEVELAND, Feb. 3, 2015 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 17th annual BIO CEO & Investor Conference to be held on February 9-10, 2015 in New York, NY, at The Waldorf Astoria New York.

Gil Van Bokkelen, Chairman and Chief Executive Officer, will present on Tuesday, February 10, 2015 at 11:00 a.m. EST in the Park North Room.

The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly-traded and select private biotech companies. Because its mission is to support industry-wide success, BIO presents a broad and unbiased view of investment opportunities and provides an annual forum for institutional investors, industry analysts, and senior biotechnology executives to shape the future investment landscape of the industry.

To listen to the live audio webcast of the presentation during the event, please visit: www.athersys.com. A replay of the webcast will be available for 90 days after the initial presentation.

About Athersys

Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.

CONTACT: William (B.J.) Lehmann, J.D.
         President and Chief Operating Officer
         Tel: (216) 431-9900
         bjlehmann@athersys.com

company logo